SL Swiss Lipid Navigator
Demonstration prototype — synthetic data only, simplified rules, not for clinical use.
Step 10 of 10 · Decision support

Summary

What this step shows

All results for this patient in one view, with the reasoning behind each step. Update any value and the results are recalculated.

Marc Favre
DEMO-2 · 64 years · Male · born 26.05.1962 · LDL-C measured 22.08.2026
Update lab values
Clinical pathwaySecondary Prevention
Risk categoryVery High
LDL-C (current)2.1 mmol/L
LDL-C target<1.4 mmol/L
Current treatmentHigh-intensity statin (Atorvastatin 80 mg)
Recommended next stepAdd ezetimibe to the current statin therapy
Swiss reimbursement Not applicable at this stage
Reasoning by step
  1. Step 5 — Clinical pathway View details →
    Secondary Prevention

    Patient has established atherosclerotic cardiovascular disease. This automatically places them on the secondary-prevention pathway — no risk score is needed to classify risk.

  2. Step 6 — Cardiovascular risk View details →
    Very High

    Per standard risk stratification, established atherosclerotic cardiovascular disease is automatically classified Very High risk — no numeric score is calculated.

  3. Step 7 — LDL-C target View details →
    <1.4 mmol/L

    Very High risk → target <1.4 mmol/L (and ≥50% reduction from baseline where baseline is known).

  4. Step 8 — Treatment plan View details →
    Add ezetimibe to the current statin therapy

    Maximally tolerated statin therapy is in place but ezetimibe has not been added yet — add it before considering injectable therapy.

  5. Step 9 — Swiss reimbursement View details →
    Not applicable at this stage

    This engine only activates once a PCSK9 inhibitor (or another reimbursement-restricted therapy) is clinically proposed. For this patient, the Treatment Engine recommended a different next step, so no reimbursement check is needed yet.

Demonstration output based on simplified rules — not clinical advice. Generated 02.11.2026 17:30.

← Swiss reimbursement
Back to patients →